Junaid Syed, MD
Psychiatry · Saint Louis, MONPI 1942381579
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Avanir Pharmaceuticals, Inc. at 27.3% of the total. Reporting peaked in 2023 at $3,943 and has fallen 75.4% since, to $969 in 2025. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 236 payments — averaging $45.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$3K
- Boehringer Ingelheim$2K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$815
- Johnson & Johnson$669
- Neurocrine Biosciences, Inc.$612
- plus $2K from 17 others
Across 686 payments — averaging $12,279 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$1.9M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.8M
- E.r. Squibb & Sons, L.L.C.$1M
- Sumitomo Pharma America, Inc.$987K
- Eli Lilly$791K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$578K
- plus $1.3M from 12 others
What the payments were for
- Travel & lodging$4,49242%
- Food & beverage$6,08857%
- Education$871%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | 20 | $2,915 |
| Boehringer Ingelheim | 5 | $2,482 |
| Alkermes, Inc. | 35 | $1,165 |
| Teva Pharmaceuticals USA, Inc. | 48 | $815 |
| Johnson & Johnson(2 entities) | 30 | $669 |
| Neurocrine Biosciences, Inc. | 17 | $612 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $470 |
| Acadia Pharmaceuticals Inc | 11 | $439 |
| Otsuka America Pharmaceutical, Inc. | 7 | $230 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $147 |
| Indivior Inc. | 8 | $126 |
| Lundbeck LLC | 5 | $119 |
| Biogen | 5 | $102 |
| Vanda Pharmaceuticals Inc. | 5 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| UCB, Inc. | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| AbbVie | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Tris Pharma Inc | 1 | $23 |
| Lilly USA, LLC | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$940
- ARISTADA$480
- INGREZZA$265
- NUPLAZID$246
- INVEGA SUSTENNA$123
- INVEGA TRINZA$123
- INVEGA$123
- SPRAVATO$123
- UZEDY$121
- ARISTADA INITIO$120
- REXULTI$110
How this compares
$10,667 in reported general payments places this provider in the 90th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 454 | $1,507,444 |
| IngrezzaValbenazine Tosylate | 148 | $727,945 |
| Invega TrinzaPaliperidone Palmitate | 24 | $211,069 |
| Risperdal ConstaRisperidone Microspheres | 162 | $200,708 |
| UzedyRisperidone | 41 | $134,172 |
| AustedoDeutetrabenazine | 19 | $110,069 |
| Abilify MaintenaAripiprazole | 34 | $101,200 |
| Clozapine OdtClozapine | 145 | $70,594 |
| Clozapine | 1,183 | $65,727 |
| VraylarCariprazine Hcl | 91 | $64,824 |
| LybalviOlanzapine/Samidorphan Malate | 39 | $61,779 |
| Aripiprazole | 725 | $56,060 |
| Paliperidone ErPaliperidone | 373 | $55,260 |
| CaplytaLumateperone Tosylate | 32 | $54,117 |
| RexultiBrexpiprazole | 72 | $52,516 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $669 | $1,919,221640 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $612 | $727,945148 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy, Austedo | $815 | $244,24160 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $230 | $153,716106 claims |
| Alkermes, Inc.Lybalvi, Aristada | $1,165 | $112,36453 claims |
| AbbVieVraylar | $29 | $64,82491 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $470 | $54,11732 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $13 | $42,9801,175 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $2,915 | $36,96232 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $30 | $29,25828 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $59 | $20,67984 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Saint Louis
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- George GrossbergSaint Louis$501K
- Christopher LoyndSaint Louis$265K
- Devnandini RastogiSaint Louis$261K
- Michael StotlerSaint Louis$250K
- James ChoSaint Louis$118K
- Steven HarveySaint Louis$90K
- Kevin BlackSaint Louis$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.